经皮冠状动脉介入治疗后他汀类药物二级预防治疗中的惰性：一项基于全国人群的队列研究。 - Suppr

Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study.

作者信息

Seo Young-Hoon, Hong Jee-Young, Kim Yong-Kyun, Kim Ki-Hong, Kwon Taek-Geun, Bae Jang-Ho

机构信息

Division of Cardiology, Cardio-Cerebrovascular Center, Konyang University Hospital, 158, Gwanjeodong-Ro, Seo-Gu, Daejeon, 35365, Republic of Korea.

Biomedical Research Institute, Konyang University Medical Center, Daejeon, Republic of Korea.

出版信息

BMC Cardiovasc Disord. 2025 Aug 9;25(1):595. doi: 10.1186/s12872-025-05081-0.

DOI:10.1186/s12872-025-05081-0

PMID:40783721

Abstract

摘要

相似文献

Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study.

BMC Cardiovasc Disord. 2025 Aug 9;25(1):595. doi: 10.1186/s12872-025-05081-0.

Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention.

Tex Heart Inst J. 2024 Dec 17;51(2):e238372. doi: 10.14503/THIJ-23-8372. eCollection 2024 Jul-Dec.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.

Interaction Between Statin Use, Coronary Artery Disease Phenotypes, on Computed Tomography Angiography, and Cardiovascular Outcomes.

JACC Cardiovasc Imaging. 2025 Jul 21. doi: 10.1016/j.jcmg.2025.05.018.

The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis.

Am J Cardiovasc Drugs. 2025 Jan 15. doi: 10.1007/s40256-024-00719-4.

Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population.

Cardiovasc Diabetol. 2025 May 31;24(1):233. doi: 10.1186/s12933-025-02798-2.

Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.

BMC Cardiovasc Disord. 2022 Nov 8;22(1):474. doi: 10.1186/s12872-022-02932-y.

Statin Overuse in Cerebral Ischemia Without Indications: Systematic Review and Annual US Burden of Adverse Events.

Stroke. 2024 Aug;55(8):2022-2033. doi: 10.1161/STROKEAHA.123.044071. Epub 2024 Jun 14.

Effect of statin therapy on coronary inflammation assessed by pericoronary adipose tissue computed tomography attenuation.

Eur Heart J Cardiovasc Imaging. 2025 Apr 30;26(5):784-793. doi: 10.1093/ehjci/jeaf062.

High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention.

J Am Heart Assoc. 2018 Nov 6;7(21):e009517. doi: 10.1161/JAHA.118.009517.

本文引用的文献

Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry).

J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106. Epub 2024 Dec 11.

Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry.

Eur J Prev Cardiol. 2024 Nov 11;31(15):1806-1816. doi: 10.1093/eurjpc/zwae170.

Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.

JAMA. 2023 Apr 4;329(13):1078-1087. doi: 10.1001/jama.2023.2487.

Overcoming Therapeutic Inertia as the Achilles' Heel for Improving Suboptimal Diabetes Care: An Integrative Review.

Endocrinol Metab (Seoul). 2023 Feb;38(1):34-42. doi: 10.3803/EnM.2022.1649. Epub 2023 Feb 16.

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.

Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18.

High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.

J Am Coll Cardiol. 2022 May 10;79(18):1802-1813. doi: 10.1016/j.jacc.2022.02.048.

Prevalence of statin intolerance: a meta-analysis.

Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.

Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis.

Diabetes Obes Metab. 2021 Sep;23(9):2137-2154. doi: 10.1111/dom.14455. Epub 2021 Jun 27.

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.

Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289. doi: 10.1093/eurjpc/zwaa047.

Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects.

J Am Heart Assoc. 2020 Nov 17;9(22):e017915. doi: 10.1161/JAHA.120.017915. Epub 2020 Nov 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献